Inventor · disambiguated record
Xiangdong Qu
Also filed as: QU XIANGDONG
8 granted patents·10 pending applications·51 citations·filing 2014–2023
84Inventor score
Files withQURE BIOTECHNOLOGY SHANGHAI CO LTD7JIANGSU HENGRUI MEDICINE CO4SUZHOU SUNCADIA BIOPHARMACEUTICALS CO LTD3QUREBIO LTD2Shanghai hengrui pharmaceutical co ltd2
Top patents by PatentIndex Score
18 records- 0194US10905743B2Interleukin 15 protein complexJIANGSU HENGRUI MEDICINE CO·Filed 2015·Granted Feb 2, 2021·9 cites·10 claims
- 0292US10344090B2PD-1 antibody, antigen-binding fragment thereof, and medical application thereofShanghai hengrui pharmaceutical co ltd·Filed 2014·Granted Jul 9, 2019·15 cites·27 claims
- 0391US11717559B2Interleukin 15 protein complex and use thereofJIANGSU HENGRUI MEDICINE CO·Filed 2020·Granted Aug 8, 2023·2 cites·15 claims
- 0490US10206980B2IL-15 heterodimeric protein and uses thereofShanghai hengrui pharmaceutical co ltd·Filed 2014·Granted Feb 19, 2019·20 cites·19 claims
- 0586US11365255B2PD-1 antibody, antigen-binding fragment thereof, and medical application thereofSUZHOU SUNCADIA BIOPHARMACEUTICALS CO LTD·Filed 2019·Granted Jun 21, 2022·2 cites·12 claims
- 0683US10815304B2PD-L1 antibody, antigen-binding fragment thereof and medical application thereofSUZHOU SUNCADIA BIOPHARMACEUTICALS CO LTD·Filed 2016·Granted Oct 27, 2020·3 cites·25 claims
- 0759US11780923B2PD-L1 antibody, antigen-binding fragment thereof and medical application thereofSUZHOU SUNCADIA BIOPHARMACEUTICALS CO LTD·Filed 2020·Granted Oct 10, 2023·0 cites·23 claims
- 0852US2024059791A1Trifunctional fusion protein containing tumor-associated antigen (taa) antibody and application thereofQUREBIO LTD·Filed 2021·Application pending·0 cites
- 0951US10793643B2PCSK9 antibody, antigen-binding fragment thereof, and medical application thereofJIANGSU HENGRUI MEDICINE CO·Filed 2016·Granted Oct 6, 2020·0 cites·24 claims
- 1051US2024043567A1Bispecific antibody and application thereofQUREBIO LTD·Filed 2021·Application pending·0 cites
- 1145US2025206823A1Antigen targeting, anti-cd16a, and immune effector cell activating trifunctional fusion protein, and application thereofQURE BIOTECHNOLOGY SHANGHAI CO LTD·Filed 2022·Application pending·0 cites
- 1245US2024383985A1Antigen targeting, anti-cd16a, and immune effector cell activating trifunctional fusion protein, and application thereofQURE BIOTECHNOLOGY SHANGHAI CO LTD·Filed 2022·Application pending·0 cites
- 1344US2024294640A1Anti-cd3 antibody variant, fusion protein, and applicationQURE BIOTECHNOLOGY SHANGHAI CO LTD·Filed 2022·Application pending·0 cites
- 1444US2025326840A1BISPECIFIC ANTIBODY TARGETING SIRP-alpha AND PD-L1 OR ANTIGEN-BINDING FRAGMENT THEREOF AND USEQURE BIOTECHNOLOGY SHANGHAI CO LTD·Filed 2023·Application pending·0 cites
- 1539US2020270365A1Pcsk9 antibody, antigen-binding fragment thereof, and medical uses thereofJIANGSU HENGRUI MEDICINE CO·Filed 2016·Application pending·0 cites
- 1637US2024018255A1ANTI-SIRPalpha ANTIBODY OR ANTIGEN-BINDING FRAGMENT THEREOF, AND USE THEREOFQURE BIOTECHNOLOGY SHANGHAI CO LTD·Filed 2021·Application pending·0 cites
- 1736US2023183352A1Bispecific antibody targeting human claudin and human pdl1 proteins, and application thereofQURE BIOTECHNOLOGY SHANGHAI CO LTD·Filed 2021·Application pending·0 cites
- 1832US2022235128A1Anti-cldn antibody and pharmaceutical composition thereof and detection method thereforQURE BIOTECHNOLOGY SHANGHAI CO LTD·Filed 2020·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Xiangdong Qu files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →